-
1.发明申请Compositions and methods comprising proteinase activated receptor antagonists 审中-公开包含蛋白酶活化受体拮抗剂的组合物和方法公开(公告)号：US20060063930A1
公开(公告)日：2006-03-23
申请号：US11208460
申请日：2005-08-19
申请人： Gregory Agoston , Todd Hembrough , Theresa LaVallee , Jamshed Shah , Lita Suwandi , Anthony Treston
发明人： Gregory Agoston , Todd Hembrough , Theresa LaVallee , Jamshed Shah , Lita Suwandi , Anthony Treston
IPC分类号： C07D261/18 , C07D235/30 , C07D403/02
CPC分类号： C07D295/185 , C07D205/04 , C07D207/34 , C07D213/56 , C07D213/82 , C07D231/40 , C07D233/64 , C07D235/26 , C07D235/30 , C07D241/26 , C07D249/04 , C07D261/18 , C07D275/03 , C07D277/46 , C07D403/06 , C07D487/04
摘要： Compositions and methods comprising proteinase activated receptor antagonists are provided. More particularly, the present invention relates to the use of proteins, peptides and molecules that bind to proteinase activated receptor 2, and inhibit the processes associated with the activation of that receptor. More specifically, the present invention provides novel compositions and methods for the treatment of disorders and diseases such as those associated with abnormal cellular proliferation, angiogenesis, inflammation and cancer.
摘要翻译： 提供了包含蛋白酶激活的受体拮抗剂的组合物和方法。 更具体地，本发明涉及结合蛋白酶活化受体2的蛋白质，肽和分子的用途，并且抑制与该受体活化相关的过程。 更具体地，本发明提供了用于治疗疾病和疾病的新型组合物和方法，例如与异常细胞增殖，血管生成，炎症和癌症相关的疾病和疾病。
-
公开(公告)号：US20070004689A1
公开(公告)日：2007-01-04
申请号：US11489263
申请日：2006-07-19
摘要： Compositions and methods for treating mammalian diseases or conditions characterized by undesirable angiogenesis by administering an effective amount of a compound of the formulae: wherein Ra is selected from —OCH3, —OCH2CH3 or —CCCH3; and Z is selected from >C(H)—OH, >C(H)—O-alkyl, >C(H)—O-sulfamate, or >C(H)-dioxolane, where alkyl is a linear, branched and/or cyclic hydrocarbon chain comprising 1 to 10 carbons.
摘要翻译： 通过施用有效量的下式化合物来治疗哺乳动物疾病或特征在于不期望的血管生成的病症的组合物和方法：其中R a a选自-OCH 3 - ， - OCH 2 CH 3或-CCH 3 3; 并且Z选自C（H）-OH，> C（H）-O-烷基，> C（H）-O-氨基磺酸酯或C（H） - 二氧戊环，其中烷基是直链，支链和 /或包含1至10个碳的环状烃链。
-
公开(公告)号：US20050203075A1
公开(公告)日：2005-09-15
申请号：US11077977
申请日：2005-03-11
CPC分类号： C07J1/00
摘要： Compositions and methods for treating mammalian diseases or conditions characterized by undesirable angiogenesis by administering an effective amount of a compound of the formulae: wherein Ra is selected from —OCH3, —OCH2CH3 or —CCCH3; and Z is selected from >C(H)—OH, >C(H)—O-alkyl, >C(H)—O-sulfamate, where alkyl is a linear, branched and/or cyclic hydrocarbon chain comprising 1 to 10 carbons.
摘要翻译： 通过施用有效量的下式化合物来治疗哺乳动物疾病或特征在于不期望的血管生成的病症的组合物和方法：其中R a a选自-OCH 3 - ， - OCH 2 CH 3或-CCH 3 3; 并且Z选自> C（H）-OH，> C（H）-O-烷基，> C（H）-O-氨基磺酸酯，其中烷基是包含1至10个的直链，支链和/或环状烃链 碳。
-
公开(公告)号：US20050014737A1
公开(公告)日：2005-01-20
申请号：US10856340
申请日：2004-05-28
CPC分类号： C07J41/00
摘要： Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula: wherein the variables are defined in the specification.
摘要翻译： 用于治疗哺乳动物疾病的组合物和方法，其特征在于不期望的血管生成，其通过施用以下通式的化合物：其中变量在说明书中定义。
-
公开(公告)号：US20070010505A1
公开(公告)日：2007-01-11
申请号：US11519570
申请日：2006-09-12
CPC分类号： C07J41/00
摘要： Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula: wherein the variables are defined in the specification.
摘要翻译： 用于治疗哺乳动物疾病的组合物和方法，其特征在于不期望的血管生成，其通过施用以下通式的化合物：其中变量在说明书中定义。
-
公开(公告)号：US20050192258A1
公开(公告)日：2005-09-01
申请号：US11118852
申请日：2005-04-29
申请人： Gregory Agoston , Jamshed Shah , Kimberly Hunsucker , Victor Pribluda , Theresa LaVallee , Shawn Green , Christopher Herbstritt , Xiaoguo Zhan , Anthony Treston
发明人： Gregory Agoston , Jamshed Shah , Kimberly Hunsucker , Victor Pribluda , Theresa LaVallee , Shawn Green , Christopher Herbstritt , Xiaoguo Zhan , Anthony Treston
CPC分类号： C07J1/00
摘要： Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula: wherein the variables are defined in the specification.
摘要翻译： 用于治疗哺乳动物疾病的组合物和方法，其特征在于通过施用以下通式的2-甲氧基雌二醇的衍生物的不期望的血管生成：其中变量在说明书中定义。
-
公开(公告)号：US20070135400A1
公开(公告)日：2007-06-14
申请号：US11701809
申请日：2007-02-02
CPC分类号： C07J41/00
摘要： Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula: wherein the variables are defined in the specification.
摘要翻译： 用于治疗哺乳动物疾病的组合物和方法，其特征在于不期望的血管生成，其通过施用以下通式的化合物：其中变量在说明书中定义。
-
公开(公告)号：US20060025619A1
公开(公告)日：2006-02-02
申请号：US11235574
申请日：2005-09-26
申请人： Gregory Agoston , Jamshed Shah , Anthony Treston
发明人： Gregory Agoston , Jamshed Shah , Anthony Treston
CPC分类号： C07J1/007
摘要： 2-methoxyestradiol having greater than 98% purity is obtained by synthetic or purification methods. This highly pure 2-methoxy estradiol, lacking estrogenic components, is particularly suitable for clinical use in humans. The purification methods of the invention involve the use of liquid-solid chromatography (LSC) to separate 2-ME2 from other compounds. The chromatographic media is preferably silica. The solvent system comprises a non-polar solvent, such as chloroform, and a polar solvent, such as methanol.
摘要翻译： 通过合成或纯化方法获得纯度大于98％的2-甲氧基雌二醇。 这种高纯度的2-甲氧基雌二醇，缺乏雌激素成分，特别适用于人类的临床应用。 本发明的纯化方法涉及使用液固固体色谱法（LSC）将2-ME2与其它化合物分离。 色谱介质优选为二氧化硅。 溶剂体系包括非极性溶剂如氯仿和极性溶剂如甲醇。
-
9.发明申请Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs 审中-公开氮取代的沙利度胺类似物的合成和抗肿瘤活性公开(公告)号：US20070105903A1
公开(公告)日：2007-05-10
申请号：US11513291
申请日：2006-08-29
申请人： Anthony Treston , Jamshed Shah , Robert D'Amato , Barry Conner , Kimberly Hunsucker , John Rougas , Glenn Swartz , Victor Pribluda
发明人： Anthony Treston , Jamshed Shah , Robert D'Amato , Barry Conner , Kimberly Hunsucker , John Rougas , Glenn Swartz , Victor Pribluda
IPC分类号： A61K31/454
CPC分类号： C07D401/04 , A61K31/454
摘要： The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, nitrogen-substituted thalidomide analogs and di-substituted thalidomide analogs have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
摘要翻译： 本发明包括有效抑制血管发生的一组化合物。 更具体地，已经显示氮取代的沙利度胺类似物和二取代的沙利度胺类似物抑制血管发生。 重要的是，这些化合物可以口服给药。
-
公开(公告)号：US20050004087A1
公开(公告)日：2005-01-06
申请号：US10896780
申请日：2004-07-21
申请人： Robert D'Amato , Shawn Green , Glenn Swartz , Jamshed Shah , John Madsen
发明人： Robert D'Amato , Shawn Green , Glenn Swartz , Jamshed Shah , John Madsen
IPC分类号： A61K31/40 , A61K31/4035 , A61K31/454 , A61K31/56
CPC分类号： A61K31/40 , A61K31/19 , A61K31/4035 , A61K31/44 , A61K31/445 , A61K31/454 , A61K31/535
摘要： The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, the invention comprises the compound EM-138 and its use in the inhibition of angiogenesis and treatment of angiogenesis associate diseases, including the inhibition of tumor growth and metastasis.
摘要翻译： 本发明包括有效抑制血管发生的一组化合物。 更具体地，本发明包括化合物EM-138及其在抑制血管发生和治疗血管生成相关疾病中的用途，包括抑制肿瘤生长和转移。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.032 秒)
